2025年,综合生物制药公司每股损失0.03美元,收入下降10.3%,原因是两个关键客户的销售疲软。 Integrated BioPharma lost $0.03 per share in Q4 2025, with revenue down 10.3% due to weak sales from two key customers.

综合生物制药公司报告说,在2025年12月31日终了期间,每股季度损失0.3美元,收入下降10.3%至1 130万美元,原因是两个主要客户的表现不佳。 Integrated BioPharma reported a quarterly loss of $0.03 per share for the period ended December 31, 2025, with revenue falling 10.3% to $11.3 million, driven by weaker performance from two major customers. 该公司的业务损失为90万美元,而2024年同一季度为20万美元,净收入从10万美元下降到80万美元。 The company posted an operating loss of $0.9 million, compared to $0.2 million in the same quarter of 2024, and saw net income drop to a loss of $0.8 million from $0.1 million. 在这六个月里,收入下降8.4%,降至2 400万美元,净损失60万美元,而2024年净损失40万美元。 For the six months, revenue declined 8.4% to $24.0 million, with a net loss of $0.6 million versus $0.4 million in 2024. 该公司在美国和卢森堡开展业务,生产和分发维生素、补充剂和草药产品。 The company operates in the U.S. and Luxembourg, producing and distributing vitamins, supplements, and herbal products.